Neurotech International Ltd
Research Neurotech International Ltd (NTI) on Bullrun: market cap AUD 25.86M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerNTI
- ExchangeAU
- CountryAustralia
- SectorHealthcare
- IndustryBiotechnology
- CurrencyAUD
- Market capAUD 25.86M
- Financial periodFY2025
- RevenueAUD 238
- Revenue growth-87.9%
- Net income-AUD 10.60M
- Free cash flow-AUD 9.02M
- Gross margin100.0%
Valuation Snapshot
latest market cap is AUD 25.86M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | AUD 238 | -AUD 10.60M | -AUD 9.02M | 100.0% | -0.01 | AUD 3.03M | n/a | AUD 2.95M |
| FY2024 | AUD 1.96K | -AUD 5.07M | -AUD 4.60M | -298.9% | -0.01 | AUD 11.63M | n/a | AUD 11.90M |
| FY2023 | AUD 5.96K | -AUD 7.79M | -AUD 6.32M | 100.0% | -0.01 | AUD 5.03M | n/a | AUD 3.96M |
| FY2022 | AUD 38.29K | -AUD 3.36M | -AUD 2.96M | 11.1% | 0 | AUD 1.90M | n/a | AUD 1.43M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-13 | AUD 25.86M | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 AUD.
About Neurotech International Ltd
Neurotech International Limited, a clinical-stage biopharmaceutical development company, focuses on development of solutions for paediatric neurological disorders with a broad-spectrum oral cannabinoid drug therapy in Australia. The company develops NTI164 to treat autism spectrum disorder, paediatric autoimmune neuropsychiatric disorders associated with streptococcal infections, paediatric acute-onset neuropsychiatric syndrome, and Rett syndrome. It also engages in executing medical research projects;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Neurotech International Ltd's market cap?
Neurotech International Ltd's market capitalization is AUD 25.86M.
What does Neurotech International Ltd do?
Neurotech International Limited, a clinical-stage biopharmaceutical development company, focuses on development of solutions for paediatric neurological disorders with a broad-spectrum oral cannabinoid drug therapy in Australia. The company develops NTI164 to treat autism spectrum disorder, paediatric autoimmune neuropsychiatric disorders associated with streptococcal infections, paediatric acute-onset neuropsychiatric syndrome, and Rett syndrome. It also engages in executing medical research projects; and developing technological devices.